Zealand Pharma and Generate Biomedicines sign $1.2 billion AI agreement
Zealand Pharma and Generate Biomedicines have signed a collaboration and license agreement on AI-engineered protein therapeutics for metabolic diseases. The value is reportedly $1.2 billion, and the announcement appeared on 13–14 October.
Who is affected and how
- pharmaceuticals
- AI-driven protein design in obesity and metabolic diseases could also speed up partner searches by competitors.
Sources
- Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseasesglobenewswire · Oct 13, 2026
- Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases | Generate:Biomedicinesgeneratebiomedicines.com · Oct 13, 2026
- Zealand Pharma pens $1.2bn AI obesity drug discovery pact with Generateyahoo finance · Oct 14, 2026
- Zealand Pharma pens $1.2bn AI obesity drug discovery pact with Generate - Pharmaceutical Technologypharmaceutical-technology.com · Oct 14, 2026
Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.